P

Puma Biotechnology

D
PBYI
USD
0.055
(2.2%)
Market Closed
3,567.00
Volume
0.31
EPS
-
Div Yield
13.447
P/E
125,314,377.27
Market Cap
Today
2.2000%
1 Week
1.793%
1 Month
-9.558%
6 Months
-40.443%
12 Months
-14.548%
Year To Date
-41.129%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
N
NKTR
0.005
(0.3953%)
USD
I
INCY
1.67
(2.5625%)
USD
J
JAZZ
1.66
(1.5152%)
USD
AZN
AZN
0.32
(0.4072%)
USD
BMY
BMY
-0.72
(-1.4475%)
USD
MRK
MRK
-1.44
(-1.2137%)
USD
NVS
NVS
-0.02
(-0.0172%)
USD

Title:
Puma Biotechnology

Sector:
Healthcare
Industry:
Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Do you need help or have a question?
Contact Us